CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company. is engaged in developing Probody therapeutics that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as targets, such as CD-166.
| Website: | www.cytomx.com |
| Main Phone: | +1 650 515-3185 |
| Address: | 343 Oyster Point Boulevard |
| Address 2: | Suite 100 |
| State: | CA |
| City / Town: | South San Francisco |
| Country: | USA |
| Postal Code: | 94080 |
| Exchange: | NGS |
| Employees: | 65 |
| NAICS: | Pharmaceutical P |
| Last Price 14.39 | Change $ 0.13 | Change % 0.91 | Tick N/A |
| Bid 11.66 | Bid Size 100.00 | Ask 17.00 | Ask Size 200.00 |
| Open 14.35 | High 14.75 | Low 14.20 | Prev Close 14.26 |
| Last Trade | Volume 529,833 | 52 Wk Hi 20.02 | 52 Wk Low 9.10 |
| Market Cap 528.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 36,749,732.00 | EPS (TTM) -1.41 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 16 | 34 |
| Number of Buys | 4 | 19 |
| Number of Sells | 12 | 15 |
| Net Activity | -226510 | 14636551 |
| Last 10 Buys | Shares |
|---|---|
| Flynn E James | 1,000 |
| Flynn E James | 1,000 |
| Cynthia Ladd | 1,000 |
| W. Michael Kavanaugh | 1,000 |
| Frederick W. Gluck | 1,000 |
| Frederick W. Gluck | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Timothy M. Shannon | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 22 | 22 | 22 | 22 |
| Low Target Price Estimate | 17 | 17 | 17 | 17 |
| Mean Target Price Estimate | 20 | 20 | 20 | 20 |
| Standard Deviation | 2.65 | 2.65 | 2.65 | 2.65 |
| Date of Most Recent Estimate | 08/10/16 | 08/03/16 | 07/18/16 | 08/10/16 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-08-11 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 298 | 2016-08-03 |
| 8-K | Report of unscheduled material events or corporate changes. | 10 | 2016-08-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2016-06-14 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2017 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
